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Summary To assist in the description of the cellular heterogeneity present in normal and neoplastic
urothelium, a panel of monoclonal antibodies (MoAbs) was raised against human transitional cell carcinoma
(TCC) of the urinary bladder. All immunizations were carried out using whole cells and membrane
preparations from well differentiated human TCCs. Two fusions produced 145 hybridomas. Following
primary screening by ELISA and secondary screening with immunohistochemistry, three useful antibodies
were identified. MoAb 35.48 binds to all cell layers of the normal urothelium and well differentiated tumours,
but not to the majority of poorly differentiated tumours. MoAb 21.48 binds preferentially to the basal cell
layer of normal urothelium and to some well differentiated papillary TCCs, but poorly differentiated tumours
exhibit diffusely positive staining. MoAb 21.48 also shows cross-reactivity with basal cell layers of other
epithelia. MoAb 5.48 binds preferentially to the superficial cell layers of normal urothelium and well
differentiated TCCs, but exhibits less binding in poorly differentiated tumours with loss of the preferential
superficial staining. Quantitative flow cytometric studies indicate that MoAb 5.48 binds to a cell-surface
antigen which is present on significantly fewer cells of poorly differentiated tumours than on either
normal urothelium (P < 0.05), or well differentiated tumours (P =0.05).
The concept of neoplasia as a caricature of the process of
tissue renewal was initially proposed by Pierce et al. (1978)
who demonstrated in animal tumours that terminal
differentiation occurs spontaneously and can be induced in
several transplantable animal tumours (Pierce & Wallace,
1971; Wylie et al., 1972). It had long been suspected that this
might also be true of human tumours (Steel, 1977), but until
the development of the in vitro clonogenic assay, there was
little direct evidence to support this concept. Studies of
human ovarian carcinoma using a soft agar colony assay
demonstrated that only a small proportion of the total
tumour cell population is capable of forming colonies in
culture (Mackillop & Buick, 1982; Mackillop et al., 1982).
Subsequent studies of human urothelium showed similarities
between the clonogenic cells of transitional cell carcinomas
and the stem cells of the corresponding normal tissue and
that morphologically differentiated, non-proliferative cells
are numerous in the well differentiated tumours (Mackillop
et al., 1985; Bizzari & Mackillop, 1985). These data suggest
that terminal differentiation occurs in human transitional cell
carcinoma, but the lack of appropriate markers of
differentiation makes it difficult to demonstrate that the loss
of proliferative potential is linked to the acquisition of
features of differentiation. To overcome this difficulty, we
have used hybridoma technology (Kohler & Milstein, 1975)
to develop a panel of monoclonal antibodies against human
transitional cell carcinoma in an attempt to identify markers
of differentiation which could be used to study the cellular
heterogeneity of human bladder cancer. Fresh human tissue
was used for immunizations and for both primary and
secondary screening. Tumour cell lines have not been studied
because these may be poor models of primary human
tumours (Mackillop et al., 1983).
Materials and methods
Clinical material
Human TCCs were obtained from the operating rooms of
the McGill University Teaching Hospitals. Specimens were
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divided under the supervision of the pathologist with a
portion sent for routine histology and a representative
sample was made available for laboratory studies. Normal
human tissues were obtained from autopsies performed
within 6h of death from any non-neoplastic cause and were
confirmed to be normal by light microscopy. Specimens of
non-urothelial malignancies were obtained from the tumour
bank at the McGill Cancer Centre.
Membrane preparations
The procedure for the production of membrane preparations
has previously been described by Bates et al. (1985).
Immunization
The method used for immunization is essentially as described
by Major et al. (1987). Briefly, 8 week old BALB/c female
mice (Charles River Canada Inc., Constant, Quebec) received
i.p. injections of 5 x 106 whole tumour cells in incomplete
Freund's adjuvant monthly for 5 months. The mice received
material from three different well differentiated TCCs. In the
seventh month, 300pg of the membrane preparation from a
fourth well differentiated TCC was injected at two s.c. sites;
one week later, three days before fusion, 15pg of a fifth
membrane preparation was injected intravenously.
Cellfusion and hybrid selection
The technique of cell fusion between immunized mouse
spleen cells and the Sp2/0-Agl4 (Sp2) fusion partner
(Shulman et al., 1978) and the method of hybrid selection
have been described previously by Major et al. (1987).
Screening ofhybridoma supernatants
ELISA Initial screening of hybridoma supernantants was
performed using an enzyme-linked immunosorbent assay
(ELISA) as described previously (Major et al., 1987). All
supernatants were screened against the membrane TCC
preparation used for the final boost and against a
preparation from normal human liver.
Avidin/Biotin immunoperoxidase staining Five-micron frozen
and paraffin tissue sections were cut and mounted on
gelatin-coated (Tissue Grip, Fisher) and glue-coated glass
microscope slides, respectively. Secondary screening of
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monoclonal antibody supernatants was done using the
avidin/biotin immunoperoxidase staining technique as
described by Hsu et al. (1981). Control sections were labelled
with P3 (Horibata & Harris, 1970), an IgG antibody secreted
by BALB/c mice myeloma cells.
Isotype determination
An ELISA and the Zymed MonoAb-ID EIA kit reagent
(Zymed, Burlingame, Ca.) were used following the
manufacturer's recommended procedure.
Indirect immunofluorescence
Cell suspensions were prepared mechanically, as described
previously (Bizzari & Mackillop, 1985). One million cells
were suspended in 100pl monoclonal antibody supernatant
and incubated at 4"C for 30min. Three millilitres of cold
alpha-minimal essential medium (Gibco, Burlington,
Ontario), supplemented with 10% foetal calf serum (Gibco)
and 1% penicillin-streptomycin (30 IU ml -I and 30 pgml-;
Flow Laboratories, Mississuaga, Ontario), were added and
the samples were centrifuged for 5min at 800g. This washing
step was repeated twice. The cells were then resuspended in
100pl fluorescein-conjugated f(ab')2 fragment goat
antimouse IgM (Cooper Biomedical, West Chester, Pa.), and
incubated at 4°C for 30 min. The cells were washed, and
resuspended in PBS for flow cytometry. Control samples
were labelled with an irrelevant primary antibody; P3 as an
IgG negative control, and BN18 (Sullivan et al., 1986), a
mouse monoclonal antibody raised against rat myeloblasts,
as an IgM negative control.
Flow cytometry
Single-cell suspensions were analysed using a fluorescence-
activated cell sorter (FACS-I1I; Becton-Dickinson, Mountain
View, Ca.) linked to a custom-built microcomputer capable
of displaying three-parameter data in real time (Stewart &
Price, 1986). Fluorescence intensity was measured between
530 and 560 nm for all samples, using an excitation
wavelength of 488 nm. The data were displayed as frequency
distributions based on the analysis of 50,000 cells.
Fluorescence intensity measurements were standardized as
described previously (Ward et al., 1986).
Results
Production ofhybridomas
The hybridomas produced from two fusions have been
screened and their tissue reactivity characterized. The first
fusion produced 85 hybridomas, of which 59 were eliminated
due to cross-reactivity with normal liver during the
preliminary screening using ELISA. The second fusion
resulted in 60 hybridomas, of which 50 were likewise
eliminated. The remaining 36 antibodies were then tested
against a wide range of normal and neoplastic human frozen
tissue sections using the avidin/biotin immunoperoxidase
staining technique. Thirty-three MoAbs showed varying
degrees of cross-reactivity with other epithelia and were not
studied further. Three MoAbs however, initially showed a
degree of urothelial specificity and were selected for detailed
study on multiple samples of normal and neoplastic human
tissue.
Characteristics andspecificities of monoclonal
antibodies
The specificities of the three monoclonal antibodies were
initially established using frozen tissue sections.
MoAb 35.48 (IgG,k) was positive on all 6 normal
urothelia (Table I) and on 10 of 12 well and moderately
differentiated TCCs (grades I and II), but on only 4 of 8
poorly differentiated TCCs (grades III). The diffuse staining
Table I Binding of MoAbs to frozen urothelial tissuca
Tissue type
Normal urothelium
MoAb 5.48 MoAb 21.48 MoAb 35.48
+ + + + + + b>s
+ s>b + +
++ s>b +++
++ s>b ±++
+ + s>b + +
+ + s>b + + b>s
TCC grade I
+
+ +
+ +
+ +
+++ s>b
TCC grade II +
+ +
+ + s>b
+ + s>b
TCC grade III
+ +
+ +
+ +
++ +
+ + b>s + +
++ ++
+ +
? + +
+ +,-
?+ +
+ + b>s
? + +
+ +
+ +,?
+++
+ +
++?
+ +
++
+++
aAvidin/biotin immunoperoxidase staining of tissue sections.
+ + + =intense positivity, + + =intermediate positivity,
± =faint positivity, - =negative. Where varying levels of
binding are observed in the same section, two symbols are
assigned, the first indicating the dominant staining pattern. s>b
preferential staining of the superficial layers. b>s preferential
staining of the basal layers.
of the entire thickness of the urothelium with MoAb 35.48 in
a well differentiated TCC is shown in panel A of Figure 1
and the corresponding control is shown in panel B. There
was faint cross-reactivity with a few of the other normal and
neoplastic tissues tested (Table II and III).
MoAb 21.48 (IgG) was positive on multiple normal and
malignant tissues (Tables I, II and III). There was a marked
preferential binding to the basal layer of some normal
urothelial specimens, as shown in Panel E of Figure 1; this
binding pattern was also prevalent on a number of other
normal epithelia (Table II). A similar pattern was observed
in a few of the well differentiated papillary TCCs (Panel F,
Figure 1).
MoAb 5.48 (IgM,k) was positive on all normal urothelial
specimens tested (Table I) and on 5 of 6 there was
preferential staining of the superficial cell layers (Panel C,
Figure 1). Staining was most intense along the luminal
surface of the superficial layer. Sixteen of 20 TCCs were also
positive and in three papillary tumours there was similar
preferential staining of the superficial layers (Panel D, Figure
1). There was cross-reactivity with other normal tissues and
a few of the unrelated tumours were positive (Tables II and
III).
We subsequently studied the binding of the three MoAbs
to fixed tissue sections, in which tissue architecture is better
preserved allowing for a more detailed evaluation of the
staining pattern. We did not find any binding of MoAbs
35.48 and 21.48 to any fixed tissues tested. The antigen
bound by MoAb 5.48, however, appeared to survive the
fixation process. We observed preferential staining of the
superficial cells in all samples of normal urothelium
examined and in the majority of well and moderately
differentiated TCCs (Table IV). Staining was absent or
heterogeneous in many poorly differentiated TCCs, and the
preferential staining pattern was not present (Table IV).
Further testing of MoAb 5.48 against other human normal
and neoplastic fixed tissues revealed its preferential stainingI*T -9 'P., 1.,. ,2 , t- ) T T & '- *- ' ti3 vi
i ?''. t SP 1 t
:,.~~~ j * .F* :.
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Figure 1 Avidin/biotin immunoperoxidase staining of normal and neoplastic frozen tissue sections (A, B, E, F) and paraffin
sections (C, D), counterstained with haematoxylin. A: well differentiated TCC stained with MoAb 35.48, and B: the corresponding
negative control stained with an irrelevant monoclonal antibody (P3). C: normal urothelium stained with MoAb 5.48, D: well
differentiated TCC stained with MoAb 5.48, E: normal urothelium stained with MoAb 21.48, and F: well differentiated TCC
stained with MoAb 21.48. (All scale bars =5O,pm).442 G. DOTSIKAS et al.
Table II Binding of MoAbs to non-urothelial frozen
tissuea
Normal tissue MoAb 5.48 MoAb 21.48 MoAb 35.48
Skin + + b>s
++ b>s ++
- + + b>s -
+ + s>b + + b>s -
Oesophagus - + + b>s
+ s>b + b>s -
++ s>b + + b>s -
Stomach + + b>s
- + + b>s -
+-_
++ s>b --
Colon
++ +_
Kidney + +b +d
+ +b +d
+ +b + +d
+ +b + +d
+++ ++ _
+++ ++ _
Prostate---
Breast + + + + +
+++ ++ _
Musclec
Endothelium
aScoring system is as described in Table I; bStaining of
the distal convoluted tubule; cCardiac, skeletal and
smooth muscle tested; dStaining of both proximal and
distal convoluted tubules; s>b preferential staining of the
superficial layers and b > s preferential staining of the
basal layers.
Table III Binding of MoAbs to non-urothelial frozen tissuea
Neoplastic tissue MoAb 5.48 MoAb 21.48 MoAb 35.48
Breast
(Infilt. ductal ca.) +
Colon + + +
(Adenocarcinoma) + +,-
Kidney
(Hypernephroma) - , +
_ +_
_ + +_
Lung
(Adenocarcinoma)
+ + + + -
Pancreas +,-
(Adenocarcinoma) +
+-
Prostate
(Adenocarcinoma) - -
"Scoring system is+
aScoring system is as described in Table 1.
Table IV Binding of MoAb 5.48 to fixed urothelial tissuea
Tissue type Tissue type
Normal urothelium + s>b TCC grade II
++ s>b ++
++ s>b ++
+ + s>b + s>b
+++ s>b ++ s>b
+++ s>b ++ s>b
+++ s>b
TCC grade I -, + TCC grade III
++ s>b
+ + s>b
+ + s>b
+ + s>b -
+-+ s>b , ++
+++ s>b ++
+++ s>b ++
++
+++
aThe scoring system is as described in Table I; s>b preferential
staining of the superficial layers and b>s preferential staining of the
basal layers.
of differentiated cells in skin and along the length of the
digestive tract mucosa (Table V).
Quantitative studies were carried out using the
fluorescence-activated cell sorter (FACS-III). MoAb 5.48
was tested on single-cell suspensions derived from specimens
of normal urothelium and a group of TCCs. Figure 2
illustrates the frequency distributions of fluorescence
intensity of MoAb 5.48 and the corresponding control
samples for specimens of normal urothelium, well
differentiated TCC, and poorly differentiated TCC.
Approximately 95% of all cells in the control suspensions
had a fluorescence intensity of less than 32 fluorescence
units. This level of fluorescence was therefore arbitrarily
chosen as the discriminator between labelled and unlabelled
cells. MoAb 5.48 binds to all three samples (Figure 2), but
by using this definition of positivity (see Figure 2), a
quantitative analysis can be made of the net percentage of
positive cells (Table VI). The percentage of positive cells is
greater in the normal urothelia (P<0.05) and well
differentiated TCCs (P=0.05), than in the poorly
differentiated tumours (Table VI).
MoAbs 35.48 and 21.48 have also been studied using the
FACS, but all samples studied have been negative. Further
evaluation with the fluorescent microscope confirmed that
these MoAbs do not bind to inact cells, indicating that the
antigens are not present on the cell surface.
Discussion
The urothelium is a self-renewing tissue in which
differentiated cells are slowly lost from the luminal surface
and replaced by the processes of proliferation, migration and
differentiation of cells from the basal layer (Martin, 1962,
1967; Walker, 1959). The preferential binding of MoAb 5.48
to the superficial cell layers of normal urothelium suggests
that it binds to a cell-surface antigen which is acquired or
exposed during the process of urothelial cell differentiation.
MoAb 21.48, on the other hand, binds intracellularly to a
site which is common to several types of epithelia but is lost
as the cells migrate from the basal layer and acquire
differentiated features. The observation that monoclonal
antibodies 5.48 and 21.48 bind to well differentiated TCCs
with a pattern similar to the normal urothelium supports the
concept that cellular differentiation occurs in neoplastic
tissue as it does in normal tissue. We have previously shown
that the majority of cells in well differentiated human TCCs
are morphologically differentiated, but that only a
subpopulation of undifferentiated cells is capable of formingUROTHELIAL CELL HETEROGENEITY 443
Table V Binding of MoAb 5.48 to fixed non-urothelial tissuea
Normal tissue Neoplastic tissue
Skin
+ + s>b
s>b
s>b
s>b
+ + s>b
+ + s>b
+ + s>b
Kidney
+ b
+ +b
+ + +b
Prostate
Breast + + +
Liver
Breast
(Infilt. ductal ca.)
Breast
(Intraductal ca.)
Colon
(Adenocarcinoma)
a
20
164
12*
8
4a ++
+
Oesophagus
(Squamous cell ca.)
Oesophagus
(Adenocarcinoma)
0
x
C
a)
LL
Kidney
(Hypernephroma)
Lung
(Adenocarcinoma)
Lung
(Squamous cell ca.)
Pancreas
(Adenocarcinoma)
Prostate
(Adenocarcinoma)
c 151
12
91
61
3
e
121
+ +
b
.I
.111,
4f
3.~
+ +,
4 16 64 256 1024 4 16 64 256 1024
Fluorescence intensity
+ +, -
+ +,+ Figure 2 FACS frequency distributions of fluorescence intensity:
MoAb 5.48 labelled single cell suspensions of normal urothelium
(b), well differentiated TCC (d), and poorly differentiated TCC
(f). Panels a, c, and e show the corresponding control samples
labelled with an irrelevant IgM antibody (BN18).
Musclec Skin
(Basal cell ca.)
Skin
(Squamous cell ca.)
Stomach
(Adenocarcinoma)
Endothelium
aScoring system is as described in Table I; bStaining of the distal
convoluted tubule; cCardiac, skeletal and smooth muscle tested and
s>b preferential staining of the superficial layers.
Table VI Quantitative analysis of MoAb 5.48 binding (net
percentage of positive cells)a
Well differentiated Poorly differentiated
Normal urothelium TCC TCC
48.0 37.7 13.7
22.3 4.4 28.7
19.2 34.3 3.6
41.7 34.0 13.6
16.6 39.0 12.6
29.6+14.3b 29.9+ 14.4 14.4+9.0
aQuantitative analysis of fluorescence labelling with MoAb 5.48.
Positive and negative cells of normal and neoplastic urothelial
specimens were classified using a threshold of 32 fluorescence units
(see Figure 2); the number of cells with 32 or more units of
fluorescence was determined and expressed as a percentage of the
total. P values were determined using the Wilcoxon rank sum test
and bMean+s.d.
colonies in vitro (Mackillop et al., 1985; Bizzari & Mackillop,
1985). We now intend to use MoAbs 5.48 and 21.48 to
isolate urothelial tumour subpopulations and investigate the
relationship between cellular differentiation and proliferative
potential in these tumours.
Several groups have produced monoclonal antibodies by
immunization with bladder tumour cell lines. Some of these
initially appeared to be tumour-specific (Koho et al., 1984;
Grossman, 1983) or urothelial tumour-specific (Trejdosiewicz
et al., 1985) when tested against a panel of cell lines, but
have not been further characterized using primary human
material. Other antibodies produced against bladder tumour
cell lines, which have been at least partially characterized
using human tissue, also appear to be tumour-specific
(Masuko et al., 1984; Ben-Aissa et al., 1985), or urothelial
tumour-specific (Sasaki, 1984, Messing et al., 1984; Ben-
Aissa et al., 1985). Two groups have produced antibodies
against human tumour cell lines which appear to be
relatively specific for high grade urothelial tumours (Fradet
et al., 1986; Young et al., 1985).
Other groups have immunized with primary human
tumours as opposed to cell lines. One such antibody (OmS),
described by Fradet et al. (1984) appears to bind
homogeneously and specifically to low grade TCCs in the
same way as our antibody 35.48. Fradet also described two
antibodies which, like our 21.48, demonstrated preferential
binding to the basal layer of multiple normal epithelia.
Summerhayes et al. (1985) previously reported on a family of
monoclonal antibodies, also produced by immunization with
fresh human tumours, which show specificity for different
subpopulations of normal urothelial cells. Four of these
antibodies resemble our antibody 5.48 and these antibodies
show preferential binding to the luminal surface of the
superficial cells of normal urothelium.
++
++
Oesophagus
Stomach
Colon
+++ s>b
+++ s>b444 G. DOTSIKAS et al.
Many patients with early stage bladder cancer can be
managed conventionally by transurethral resection but a
significant proportion will ultimately develop recurrences
which are more invasive and may lead to death despite
aggressive surgical or radiotherapeutic intervention at that
time (Whitmore, 1979). Tumour grade is a powerful
prognostic factor in transitional cell carcinoma of the
urinary bladder (Barnes et al., 1977), but conventional
histology does not adequately predict the natural history of
this disease. It is possible that the use of differentiation-
specific monoclonal antibodies may refine our ability to
predict the behaviour of this tumour and permit urologic
oncologists to define the subgroup of patients with early
stage disease which requires early aggressive management for
cure.
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